Peptidefor tremors The alpha-synuclein peptide is a critical area of focus in understanding and potentially treating neurodegenerative conditions, most notably Parkinson's disease (PD). This ubiquitous presynaptic protein, encoded by the SNCA gene, plays a vital role in synaptic activity, regulating neurotransmitter release and synaptic vesicle traffickingAlpha Synuclein, Human. However, when its structure and function are disrupted, alpha-synuclein can misfold and aggregate, forming toxic oligomers and fibrils that are a hallmark of diseases like Parkinson's and Lewy body dementia. Consequently, current efforts made in the development of peptides are largely aimed at modulating this aberrant aggregation processHuman Alpha-synuclein peptide (ab17041).
The investigation into alpha-synuclein peptides is multifaceted, encompassing their role in disease pathology, the development of diagnostic tools, and the design of novel therapeutic strategies.Alpha synuclein control peptide (116-131), Purified Peptide Researchers are exploring how to prevent the formation of toxic alpha-synuclein aggregates, which are implicated in progressive neuronal death.作者：JH Torpey·2020·被引用次数：17—We probe the mechanism of action of apeptide4554W, (KDGIVNGVKA), previously identified through intracellular library screening, to prevent aSyn aggregation ... This has led to significant interest in peptides for Parkinson's disease and related synucleinopathies, with a particular emphasis on creating peptide-based interventions that can directly target and inhibit the aggregation of alpha-synuclein.
Alpha-synuclein's normal function is crucial for healthy neuronal communication. It is a small, acidic protein, approximately 14 kDa in humans, highly expressed in the brain and predominantly found in presynaptic terminals. Its interaction with synaptic vesicles is essential for efficient neurotransmission. However, under pathological conditions, alpha-synuclein undergoes conformational changes, leading to its aggregation. These aggregates are primarily observed as Lewy bodies in neurons, a key pathological feature of Parkinson's disease.Preventing the aggregation of α-synuclein(αS) into toxic oligomers and conformers is a major therapeutic goal in conditions such as Parkinson's disease and ... The accumulation of these abnormal forms of alpha-synuclein is believed to trigger selective and progressive neuronal death through various mechanisms, including mitochondrial impairment and lysosomal dysfunction.
The pathological aggregation of alpha-synuclein presents a compelling target for therapeutic intervention. Researchers are actively developing peptide-based approaches to directly target alpha-synuclein. These strategies often involve designing peptides that can either prevent the aggregation of alpha-synuclein into toxic forms or promote the clearance of existing aggregatesPurity >95%,Alpha-Synuclein (a-Synuclein) is a 14 kD (140 amino acids) acidic presynaptic protein. It is a major component of Parkinson's disease aggregates ....
One prominent area of research involves developing alpha-synuclein knockdown peptides. These peptides are engineered to reduce the expression or promote the degradation of alpha-synuclein protein.Human Alpha-synuclein peptideis a Synthetic blocking peptide. >90% and suitable for BL. View Alternative Names. chevron-down. For instance, specific peptides have been designed to facilitate the breakdown of alpha-synuclein within cells, offering a potential avenue for neuroprotection.Alpha-Synuclein Blocking Peptide | BLP-PZ035 Other peptide-based strategies focus on stabilizing native folds of alpha-synuclein or creating decoy peptides that interfere with the aggregation process.
Furthermore, some peptides are synthesized as human alpha-synuclein peptide fragments or derivatives to serve specific research purposes.Neuronal protein that plays several roles in synaptic activitysuch as regulation of synaptic vesicle trafficking and subsequent neurotransmitter release. For example, synthetic blocking peptides can be used to validate antibody binding sites or to study the immunogenic properties of alpha-synuclein. These tools are invaluable for advancing our understanding of alpha-synuclein biology and for developing diagnostic and therapeutic agents作者：JH Torpey·2020·被引用次数：17—We probe the mechanism of action of apeptide4554W, (KDGIVNGVKA), previously identified through intracellular library screening, to prevent aSyn aggregation ....
A significant portion of research centers on identifying and designing peptides that can inhibit the formation of alpha-synuclein fibrils and toxic oligomers. Studies have demonstrated that certain peptide sequences, such as those containing proline residues, can be particularly effective in preventing alpha-synuclein fibrillation. These peptides work by interfering with the self-assembly process of alpha-synuclein, thereby reducing its cytotoxicityPool of 33peptidesderived from apeptidescan (15mers with 11 aa overlap) throughAlpha-Synuclein(Swiss-Prot ID: P37840) of Human..
For example, research has explored rationally designed peptides that can significantly suppress alpha-synuclein aggregation and its associated cellular toxicity in various model systems, including yeast and human cell lines. The development of such peptides represents a promising therapeutic direction, aiming to halt or slow the progression of neurodegenerative diseases driven by alpha-synuclein pathology.Sequestration of synaptic proteins by alpha-synuclein ...
Beyond therapeutic applications, alpha-synuclein peptides are essential tools in basic research.In this project we will evaluate this treatment that holds promise to reduce protein aggregation and protect affected neurons against degeneration. They are used to generate antibodies for detection and study, as positive controls in experimental assays, and as components of peptide libraries for screening potential inhibitors. The availability of purified alpha-synuclein peptide, including specific fragments like alpha-Syn 29-40, allows researchers to investigate precise mechanisms of aggregation and toxicity.
The ongoing exploration of peptide-based approaches to directly target alpha-synuclein highlights the protein's central role in neurodegeneration.Alpha-Synuclein(α-Synuclein) is a presynaptic protein found to be a major component of Parkinson's Disease (PD) aggregates. As our understanding of alpha-synuclein's structure, function, and misfolding pathways deepens, so too does the potential for peptide-based interventions to offer novel solutions for treating debilitating neurological disorders. The development of effective peptides that can modulate alpha-synuclein aggregation remains a key goal in the scientific community's fight against Parkinson's disease and related conditions.
Join the newsletter to receive news, updates, new products and freebies in your inbox.